MedTrace Logo

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

NCT04823091 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-03-16

No results posted yet for this study

Summary

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.

Conditions

  • T-Cell Lymphocytic Leukemia
  • T-Cell Chronic Lymphocytic Leukemia
  • T Cell Non-Hodgkin Lymphoma

Interventions

DRUG

Fludarabine + Cyclophosphamide + CAR7-T Cells

fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.

Sponsors & Collaborators

  • Beijing GoBroad Hospital Management Co.,Ltd

    collaborator UNKNOWN

  • Yake Biotechnology Ltd.

    collaborator INDUSTRY

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Heng Mei · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2023-04-07
Completion
2024-04-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04823091 on ClinicalTrials.gov